Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The present trial investigates a possible use of oral bosentan, which is currently approved
for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to
patients suffering from PAH Class II.